跳至主要内容
临床试验/ACTRN12605000423617
ACTRN12605000423617已完成1 期

Phase I trial of the safety and the effect on immune parameters of an immunotherapy for glioma based on cultured autologous dendritic cells presenting autologous tumour cell antigens derived from irradiated glioma cells

Queensland Institute of Medical Research (QIMR)0 个研究点目标入组 10 人开始时间: 2005年9月16日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
1 Years 至 75 Years(—)
性别
All

入选标准

  • Confirmed Malignant Glioma, Macroscopic tumour resection, normal haematolological parameters, acceptable liver and renal function parameters.

排除标准

  • Extensive intracranial disease precluding total or subtotal resection, ECOG status >2, History of autoimmune disease or immunosuppressive therapy, Prior use of immunotherapeutic agent, Positive serology for HIV, Hep B or Hep C, Significant non-malignant disease, Pregnancy, Other malignancy, Patients in whom only biopsy or partial resection was possible.

研究者

发起方
Queensland Institute of Medical Research (QIMR)

相似试验